Tadalafil Tablet, Coated
Product Images NDC 62332-180

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 62332-180). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 5 (Tadalafil 5figure)

A line graph comparing the mean IPSS total score changes from baseline over 12 weeks in BPH patients treated with Tadalafil Tablet 5 mg versus placebo. The Y-axis shows change from baseline score, and the X-axis shows treatment duration in weeks, with Tadalafil showing a greater reduction in scores than placebo.*

FDA Label Image

Figure 6 (Tadalafil 6figure)

A line graph showing the mean IPSS (International Prostate Symptom Score) changes from baseline in BPH (Benign Prostatic Hyperplasia) patients over 12 weeks of treatment. Two lines compare Tadalafil 5 mg tablet against placebo, plotting change scores over time at 0, 1, 4, 8, and 12 weeks. The Tadalafil group shows a greater decrease in IPSS scores, with statistically significant differences marked by asterisks at weeks 4 and 12.*

FDA Label Image

Figure 7 (Tadalafil 7figure)

A line graph illustrating mean Total IPSS changes by visit in BPH patients taking Tadalafil tablets once daily combined with Finasteride compared to Placebo with Finasteride. The x-axis shows weeks of therapy (0, 4, 12, 26), and the y-axis shows least-squares mean change from baseline. Data show a greater reduction in IPSS scores for the Tadalafil/Finasteride group over time, with statistical significance indicated at multiple time points.*

FDA Label Image

Figure 8 (Tadalafil 8figure)

A line graph showing mean changes in IPSS total score over 12 weeks comparing Tadalafil 5 mg tablets and placebo in ED/BPH patients. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS score. The Tadalafil line shows a greater decrease in score than placebo over time, with statistically significant difference marked at 12 weeks (p<0.01).*

FDA Label Image

Figure 1 (Tadalafil Figure1)

A set of four line graphs showing the difference in standing and supine systolic and diastolic blood pressures (mmHg) over time (hours) comparing Tadalafil to placebo. Each graph displays the mean difference with error bars at various time points from 0 to 96 hours after dosing.*

FDA Label Image

Figure 2 (Tadalafil Figure2)

This image contains two line graphs depicting systolic blood pressure changes (in mmHg) over 24 hours post-dose. The top graph shows standing systolic blood pressure and the bottom graph shows supine systolic blood pressure. Both graphs compare the effects of tadalafil 20 mg combined with doxazosin 8 mg versus placebo combined with doxazosin 8 mg.*

FDA Label Image

Figure 3 (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) over time (hours) after administration of tadalafil or placebo, combined with doxazosin at 8 mg once daily. The graph shows four groups: 20 mg tadalafil at 08:00 and 20:00, and placebo at 08:00 and 20:00, all with 8 mg doxazosin at 08:00. Each group is represented by distinct line styles and markers, illustrating blood pressure changes up to 12 hours post-dose.*

FDA Label Image

Figure 4 (Tadalafil Figure4)

A line chart depicting plasma tadalafil concentration (in micrograms per liter) over time (hours) following different dosing regimens. The chart compares single 20-mg and 5-mg tadalafil doses with a once-daily 5-mg tadalafil dose after five consecutive days of administration, showing concentration changes over a 120-hour period.*

FDA Label Image

Tadalafil mg5

Label for Tadalafil Tablets, USP 5 mg, coated oral tablets manufactured by Alembic Pharmaceuticals Inc. The package contains 30 tablets. The label includes storage instructions, a warning to keep out of reach of children, and dosage guidance to take the entire dose without splitting tablets. Manufactured in India and distributed by Alembic Pharmaceuticals, Inc., Bedminster, NJ, USA. Barcode and NDC 62332-178-30 are visible.*

FDA Label Image

Tadalafil Strength10

Label for Tadalafil Tablets, USP 10 mg coated oral tablets by Alembic Pharmaceuticals Inc. The label includes NDC 62332-179-30 and states a 30 tablet package size. It mentions storage instructions, dosage form, and the manufacturer's addresses in Gujarat, India, and New Jersey, USA. Warnings include keeping out of reach of children and directions on tablet usage.*

FDA Label Image

Tadalafil Strength20

Label for Tadalafil Tablets, USP 20 mg coated tablets by Alembic Pharmaceuticals Inc. The label states the tablet strength as 20 mg, the package contains 30 tablets, and includes storage instructions, dosage caution, manufacturer details (Alembic Pharmaceuticals Limited, India, and Alembic Pharmaceuticals, USA), and a barcode. The label emphasizes the tablets should not be split and be taken whole.*

FDA Label Image

Tadalafil Strength25mg

Tadalafil Tablets, USP 2.5 mg coated oral tablets packaging label from Alembic Pharmaceuticals Inc. The label indicates a prescription drug in a pack of 30 tablets (2 blisters of 15 tablets each) intended for once daily use. The label includes dosage instructions, warnings, and manufacturer details along with barcodes and NDC 62332-177-15.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of tadalafil, illustrating the molecular arrangement of its atoms and bonds as an active ingredient in the listed pharmaceutical products.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.